Nycoplus Calcigran

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Nycoplus Calcigran

Quick Facts

Property Description
Active Ingredients Calcium Carbonate and Cholecalciferol (Vitamin D3)
Form Oral Chewable Tablet
Pharmacological Class Mineral Supplement / Vitamin D Analogue
Common Use Addressing calcium and Vitamin D deficiencies
Origin Combination of inorganic salt and naturally derived vitamin

What Type of Combination Preparation is Nycoplus Calcigran?

Nycoplus Calcigran is defined as a foundational combination pharmaceutical preparation intended to address and prevent states of deficiency in both calcium and Vitamin D. This preparation belongs to the pharmacological group of Mineral supplements combined with Vitamin D analogues, which places it within the broader class of Antihypocalcemic agents. The essential purpose of this product is to support the body's calcium homeostasis, a balance clinically recognized as critical for maintaining the structural integrity of the skeletal system. Unlike single-nutrient products, this preparation delivers two essential micronutrients concurrently, which is a key differentiating factor, streamlining the necessary intake for sustained bone health maintenance in adults and the elderly.

Composition and Form: Calcium Carbonate and Cholecalciferol

The preparation contains two active ingredients: the mineral Calcium, provided as the salt Calcium Carbonate, and the fat-soluble vitamin Cholecalciferol (Vitamin D3). Nycoplus Calcigran is exclusively available as an oral chewable tablet, a distinct form designed for consumption via the oral route of administration. Calcium Carbonate is a bioavailable source of supplemental calcium frequently utilized in clinical settings. This indicates that the form of calcium used is readily available for the body's use.

Why is the Combination of Calcium and Vitamin D Necessary?

The combination of Calcium Carbonate and Cholecalciferol is necessary because the vitamin is essential for the effective use of the mineral. The core mechanism is based on Cholecalciferol actively enhancing the efficiency of the intestinal absorption of the calcium ions supplied by the Carbonate salt. This synergistic effect is key to the product's general benefit, as it ensures the body not only receives the fundamental material (Calcium) but is also physiologically prepared to incorporate it into the skeletal matrix through optimal uptake. The general purpose of this dual action is to directly support normal bone mineralization and help prevent conditions arising from inadequate mineral and vitamin D status.

Regulatory References

  1. NIH Overview of Calcium Homeostasis
Advertisements

What side effects are possible with Nycoplus Calcigran?

Possible Side Effects and Safety Information

The official safety documentation for preparations containing Calcium Carbonate and Cholecalciferol (Vitamin D3) classifies adverse reactions primarily by frequency and the body systems affected.


Frequency-Classified Adverse Reactions

The most frequently observed adverse reactions are categorized as uncommon or rare in official regulatory sources. The most significant adverse effect category involves metabolic disturbances:

  • Uncommon (affects 1 to 10 users in 1,000): Hypercalcaemia (elevated calcium in the blood) and Hypercalciuria (elevated calcium in the urine).
  • Rare (affects 1 to 10 users in 10,000): Effects on the Gastrointestinal System (e.g., constipation, flatulence, nausea, abdominal pain, diarrhea) and Skin and Subcutaneous Tissue (e.g., rash, pruritus, urticaria).

Serious Adverse Reactions and Systemic Safety

Adverse reactions classified as having frequency not known include severe Hypersensitivity Reactions (e.g., angioedema) and the Milk-Alkali Syndrome (Burnett's syndrome), a serious metabolic condition associated with excessive intake. The preparation's safety profile is centered on the Metabolism and Nutrition Disorders and the Renal and Urinary System, with risks including Nephrolithiasis (kidney stone formation).


Population-Specific Safety Considerations

The regulatory label specifies heightened caution and monitoring protocols for certain patient groups. Individuals with renal impairment face an increased risk of hypercalcaemia and renal complications. Safety notes also apply to patients with sarcoidosis due to enhanced Vitamin D metabolism, and to immobilized patients with osteoporosis. For pregnant women, use is limited strictly to correcting documented deficiency, with careful restriction of the daily dose.

Advertisements

Overdose and Emergency Response

The overdose profile for Nycoplus Calcigran is officially defined by hypercalcemia and hypercalciuria, which are consequences of excessive Cholecalciferol (Vitamin D3) and Calcium Carbonate intake. Documented overdose presentations commonly include anorexia, nausea, vomiting, excessive thirst (polydipsia), frequent urination (polyuria), abdominal pain, muscle weakness, and fatigue. These initial manifestations can escalate to serious systemic and organ complications, including cardiac arrhythmias, renal failure, and potentially irreversible permanent kidney damage.

Regulators mandate that patients seek immediate medical attention upon the suspicion or appearance of any documented overdose symptom. The required initial action is the immediate discontinuation of all calcium and vitamin D supplements. Since no specific antidote is known for the vitamin D component, management is strictly supportive. This typically involves IV rehydration and, in severe cases, the use of pharmaceutical interventions like bisphosphonates or corticosteroids. Consistent laboratory monitoring of calcium levels and kidney function is required due to the prolonged systemic effects of the toxicity. Specific population risks noted in official documentation include increased severity for patients with renal impairment and the imperative to avoid overdose in pregnant women due to potential fetal harm.

Advertisements

Therapeutic Uses of Nycoplus Calcigran

The primary therapeutic role of Nycoplus Calcigran is to provide support aimed at addressing micronutrient deficits and managing the clinical conditions and symptoms that arise from these imbalances. The combination of this vitamin with calcium is commonly used to prevent and treat certain bone diseases.

The preparation is applied across therapeutic domains involving compromised skeletal health management and antihypocalcemic therapy. It is generally used as a supportive measure in managing conditions of low bone mass and fragility, such as osteoporosis and osteomalacia, and in addressing symptoms of neuromuscular irritability, including muscle spasms and latent tetany. This approach helps address symptom clusters related to systemic imbalance.

“The combination is considered relevant for easing symptoms linked to low mineral status and supporting overall bone maintenance, particularly in populations at higher risk.”

Quick Fact: Relief for Musculoskeletal Symptoms

Property Description
Primary Use Context Supportive management of bone fragility and mineral deficiency states.
Symptom Focus Muscle spasms, involuntary cramping, and bone aching.
Patient Benefit May contribute to reducing fracture risk and improving day-to-day comfort.

This medication is applicable in clinical settings where nutritional deficiencies of calcium and Vitamin D are confirmed or anticipated. It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability, especially for older and postmenopausal patient groups.

Regulatory References

  1. MedlinePlus overview of Vitamin D3
Advertisements

Eligibility and Restrictions for Use

Eligibility Status for Nycoplus Calcigran

Nycoplus Calcigran is officially designated for use in Adults and Older Adults to address established calcium and Vitamin D deficiencies or as adjunct therapy for osteoporosis. The regulatory profile includes several absolute contraindications and defined restrictions.

Absolute Contraindications

Use is prohibited for individuals with hypersensitivity to the ingredients, hypercalcaemia (high blood calcium), hypercalciuria (high urinary calcium), or hypervitaminosis D (excess Vitamin D). The medicine is also contraindicated in patients with severe renal impairment and those with a history of nephrolithiasis (kidney stones).

Age and Conditional Use

The medicine is not recommended for Children and Adolescents under 18 years due to the fixed high dose of Vitamin D in the formulation. Conditional use requires close medical supervision for individuals with sarcoidosis or those undergoing prolonged immobilisation. During pregnancy and lactation, use is allowed only when correcting a confirmed deficiency, adhering to official daily intake limits, and considering the infant's potential exposure.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nycoplus Calcigran (Calcium Carbonate and Cholecalciferol) has documented interaction patterns that primarily involve chelation, pharmacodynamic synergy, and metabolic alteration, as defined in regulatory prescribing information. All factual statements regarding interaction risks and mandatory conditions are consistent with government health authority documentation.


Documented Interaction Patterns

Category Interacting Substances (Examples) Regulatory Constraint
Reduced Exposure of Co-administered Drug Tetracycline Antibiotics, Quinolone Antibiotics, Levothyroxine, Bisphosphonates Mandatory Timing Separation: Doses must be separated by several hours (e.g., two to six hours) to prevent the calcium component from reducing the systemic exposure of these medicines.
Increased Toxicity Risk Cardiac Glycosides (e.g., Digoxin), Thiazide Diuretics Monitoring Required: Co-administration may potentiate the toxicity of cardiac glycosides or increase the risk of hypercalcaemia due to additive effects.
Reduced Efficacy Phenytoin, Barbiturates, Rifampicin Metabolic Alteration: These substances may increase the catabolism of the Cholecalciferol (Vitamin D3) component, leading to a reduced overall therapeutic effect.

Restrictions and Special Considerations

Co-administration with other high-dose sources of Vitamin D or analogues is officially restricted due to the heightened risk of hypervitaminosis D. Specific foods high in oxalic acid (e.g., spinach) or phytic acid (e.g., whole grains) may officially reduce calcium absorption. Furthermore, patients with renal impairment are at an increased risk of hypercalcaemia from co-administration due to impaired elimination, requiring caution as noted in regulatory documents.

Advertisements

Mechanism of Action

How Nycoplus Calcigran Works

Nycoplus Calcigran's mechanism involves the concurrent action of Calcium and Cholecalciferol (D3) on mineral homeostasis and deposition. The Calcium component provides Calcium ions which are incorporated into the bone matrix, a key biological target. These ions contribute directly to the systemic Calcium pool required for fundamental osteoblast and osteoclast activity.

The Cholecalciferol component undergoes two hydroxylation steps: first in the liver, then in the kidneys, forming its active metabolite, 1,25-dihydroxycholecalciferol (calcitriol). This metabolite acts as an agonist for the Vitamin D Receptor (VDR), a nuclear transcription factor expressed in target tissues like the intestinal epithelial cells. Activation of the VDR initiates a downstream cascade that mediates the increased synthesis of calcium-binding proteins (e.g., calbindin). This intracellular process facilitates the intestinal absorption of Calcium, resulting in the modulation of systemic Calcium levels.

Advertisements

Dosage and Administration Information

How to Use Nycoplus Calcigran

This section outlines the usage protocol for Nycoplus Calcigran.


Administration Scope

Instruction Detail
Route of administration: Oral
Dosing schedule: One chewable tablet twice daily
Timing in relation to meals: Can be taken independent of meals, although administration timing may be adjusted to avoid interactions with certain co-administered medications.
Preparation requirements: None; the medication is a ready-to-use chewable tablet.
Age-group administration rules: The product is not intended for use in children.
Missed-dose rules: The patient must not take a double dose to compensate for a forgotten tablet.
Special procedural conditions: Use is subject to restrictions in patients diagnosed with severe impairment of kidney function.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Oral
Frequency pattern: Daily (divided dosing)
Basis: Pharmacological specifications
Use-context constraints: Restricted use in specific patient populations due to physiological status (e.g., severe renal impairment).

Resulting Procedural Structure

Step sequence:

  • Consume the dose: The patient must ingest one chewable tablet.
  • Method of intake: The tablet must be chewed or sucked and not swallowed whole.
  • Frequency: This step must be repeated twice daily to meet the full labeled dosing requirement.

This protocol defines the continuous administration of the preparation and mandates the specific method (chewing or sucking) for proper ingestion, ensuring the medicine is used according to its formulation.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Nycoplus Calcigran contains a combination of calcium carbonate and cholecalciferol (Vitamin D3). The primary body of research surrounding this combination focuses on its role in supporting bone mineral density and addressing nutritional deficiencies, particularly in populations at risk of osteoporosis.

Evidence in Bone Health

Clinical trials have explored the effect of combined calcium and Vitamin D3 supplementation, often alongside prescription therapies, for individuals diagnosed with osteoporosis. Studies have demonstrated that adequate intake of these components is necessary for the efficacy of some anti-resorptive medications used in osteoporosis management.

Research involving the combination of calcium and cholecalciferol has focused on evaluating changes in bone mineral density (BMD) and the potential association with fracture risk. Meta-analyses of randomized controlled trials (RCTs) indicate that supplementation may be associated with a reduced risk of total fractures, including hip fractures, particularly in individuals with pre-existing Vitamin D deficiency or institutionalized populations.

Role of Vitamin D3

The component cholecalciferol (Vitamin D3) is critical for the body's absorption of calcium from the intestine. Research shows that insufficient Vitamin D levels can lead to secondary hyperparathyroidism, which may accelerate age-related bone loss. Supplementation aims to maintain sufficient levels of 25-hydroxyvitamin D in the blood, which is necessary for normal bone mineralization and maintenance.

Component Primary Mechanism Studied
Calcium Carbonate Building and maintaining bone mass
Cholecalciferol (D3) Enhancing intestinal absorption of calcium

Further investigation continues to clarify the precise relationship between specific doses of Vitamin D and calcium on outcomes in healthy, community-dwelling adults versus those with diagnosed deficiencies or bone disorders.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nycoplus Calcigran (FAQ)


Q: Is Nycoplus Calcigran the same as Calcigran Forte?

Official product information describes Nycoplus Calcigran and Calcigran Forte as separate preparations that both contain the active ingredients calcium carbonate and cholecalciferol (Vitamin D3). While they share the same components, preparations with different names may vary in strength, specific formulation details, or local regulatory approval status.


Q: Can Nycoplus Calcigran cause constipation?

Official documentation for this type of combination medicine lists effects on the digestive system as potential adverse reactions. This includes constipation, which is often classified as rare in official sources, meaning it affects a very small number of users.


Q: Does Nycoplus Calcigran interact with thyroid medication?

Regulatory information indicates that Nycoplus Calcigran is documented to interact with thyroid medications like Levothyroxine. Regulatory documents describe a required separation of several hours between the intake of this product and thyroid medicine to prevent reduced systemic exposure of the thyroid medicine.


Q: What is the role of calcium and vitamin D in this medicine?

The combination works together: the calcium component provides structural material for bone, and the Vitamin D component is necessary to help the body absorb that calcium effectively. This action supports the body's mineral homeostasis and bone structural integrity.


Q: Is Nycoplus Calcigran suitable for people with lactose intolerance?

The official documentation lists specific excipients (inactive ingredients) in the formulation, which can include certain sugars or sugar alcohols such as isomalt or sucrose. If there are known sensitivities to lactose or specific excipients, official product information contains the full list of ingredients for review.


Q: Is there any research that supports the use of Nycoplus Calcigran?

Studies on the combination of calcium and Vitamin D3 support its use for bone health. Research indicates that this type of supplementation may be associated with a reduced risk of total and hip fractures, especially in individuals with existing Vitamin D deficiency or those at high risk of osteoporosis.


Q: Why is the calcium carbonate form used in Nycoplus Calcigran?

Regulatory documents identify the salt as Calcium Carbonate. This form is described as a bioavailable source of supplemental calcium often utilized in clinical settings. The active ingredients are supplied in this form to support the product's intended action.


Q: What is the difference in effect between a chewable tablet and a regular pill?

The regulatory documents require the tablet to be chewed or sucked and not swallowed whole. This method of administration is specific to the chewable tablet formulation and supports the proper dissolution of ingredients, which is essential for the medicine's function.


Q: Can I crush or split the Nycoplus Calcigran tablets?

The official instruction for this medicine specifies that the tablet must be consumed by chewing or sucking it, not swallowing it whole. The method of ingestion is defined by the product's design, as described in the official administration documents.


Q: Does taking Nycoplus Calcigran at a certain time of day matter?

Official instructions specify taking the medicine twice daily, but state that it generally can be taken independent of meals. The timing of intake may be adjusted to avoid interactions with certain co-administered medications, as described in the official documentation.


Q: Is Nycoplus Calcigran a prescription medicine or over-the-counter?

Nycoplus Calcigran is often classified in regulatory documents as a non-prescription product, meaning it is available over-the-counter. Its primary use is for treating or preventing states of calcium and Vitamin D deficiency.


Q: Are there any known interactions between Nycoplus Calcigran and coffee or tea?

Official documents note that specific substances in certain foods, such as oxalic or phytic acid, may reduce calcium absorption. While coffee or tea are not explicitly named in regulatory warnings, the general concern relates to substances that can inhibit mineral absorption.


Q: Who is generally considered eligible to use Nycoplus Calcigran?

The product is officially designated for use in Adults and Older Adults. It is used to address established deficiencies in calcium and Vitamin D or as an additional treatment for conditions like osteoporosis.


Q: Is Nycoplus Calcigran appropriate for children?

Official regulatory documents state that the medicine is not intended or not recommended for use in Children and Adolescents under 18 years of age. This restriction is primarily due to the fixed, high dose of Vitamin D contained in the formulation.


Q: Does Nycoplus Calcigran contain sugar or sweeteners?

Official documents list excipients such as sucrose, isomalt, or sorbitol (sweeteners) in the formulation. This information is required for consumers who monitor sugar intake.


Q: What are the signs of taking too much Nycoplus Calcigran?

Symptoms of taking too much are primarily linked to hypercalcaemia, which is an elevated level of calcium in the blood. Signs may include gastrointestinal symptoms like nausea, vomiting, or constipation, as well as increased thirst or increased urination.


Q: Is there a risk of interaction with heart medications?

Official information indicates that co-administration with certain heart medications called cardiac glycosides may increase the risk of toxicity. Therefore, the regulatory label specifies that use with these types of medicines requires close monitoring.


Q: Do studies show Nycoplus Calcigran helps with fracture prevention?

Research involving the combination of calcium and cholecalciferol indicates that supplementation may be associated with a reduced risk of total fractures, including hip fractures. This effect is most often seen in specific populations, such as those with pre-existing Vitamin D deficiency.


Q: What is the significance of the strength of Nycoplus Calcigran?

The strength (e.g., 500mg/400 IU) represents the fixed amount of elemental calcium and Vitamin D3 contained in each tablet. This specific, standardized ratio is set to treat or prevent documented deficiencies as defined by the regulatory approval.


Q: Is Nycoplus Calcigran meant to be a permanent treatment?

Regulatory documents describe the product’s use for treating or preventing deficiency states and as adjunct therapy. Long-term use is associated with monitoring requirements due to the potential risk of hypercalcaemia, as outlined in the official warnings.


Q: Is it safe to use Nycoplus Calcigran long-term?

For prolonged treatment, the regulatory label specifies that patient monitoring is necessary. Specifically, blood calcium levels and kidney function (measured by serum creatinine) must be checked, especially in patients who may be at risk of developing high calcium levels.


Q: Does Nycoplus Calcigran cause fatigue or dizziness?

Neither fatigue nor dizziness is listed as a primary or common side effect in official safety documentation. However, these symptoms may be associated with severe cases of hypercalcaemia (elevated calcium in the blood), which is a potential adverse effect of the medicine.

Advertisements

How should Nycoplus Calcigran be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documentation defines mandatory conditions for storing Nycoplus Calcigran chewable tablets.

Requirement Specific Condition
Maximum Temperature Store not exceeding 30^circC (86°F).
Environmental Protection Protect from light and moisture (keep container tightly closed).
Container Rule Must be kept in the original container.

The product's stability is limited by a shelf-life of 6 months after first opening. It must not be used after the expiry date.

For safety, the medicine must be stored out of the sight and reach of children.

Regarding disposal, unused or expired medicine must be handled according to local requirements. Regulatory instructions prohibit disposal via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nycoplus Calcigran found in:

A-Z Index: